http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Tue, 01 Sep 2026 07:00:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Press+Releases/Aquestive+Therapeutics+to+Participate+in+Upcoming+September+Investor+Conferences/27008559.html <p align="justify">WARREN, N.J., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, announced today that the management team will participate in four upcoming investor conferences in September 2026 as follows:</p> <ul type="disc"><li style="text-align:justify;">2026 Wells Fargo Healthcare Conference: available to host investor meetings on Tuesday, September 8th</li><li style="text-align:justify;">Cantor Healthcare Conference: fireside chat at 3:20 pm ET and available to host investor meetings on Wednesday, September 9th</li><li style="text-align:justify;">Citi’s 2026 Biopharma Back to School Summit: available http://www.streetinsider.com/Press+Releases/Aquestive+Therapeutics+to+Participate+in+Upcoming+September+Investor+Conferences/27008559.html Tue, 01 Sep 2026 07:00:00 -0400 AQST http://www.streetinsider.com/Globe+Newswire/Aquestive+Therapeutics+to+Participate+in+Upcoming+September+Investor+Conferences/27008559.html <p align="justify">WARREN, N.J., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, announced today that the management team will participate in four upcoming investor conferences in September 2026 as follows:</p> <ul type="disc"><li style="text-align:justify;">2026 Wells Fargo Healthcare Conference: available to host investor meetings on Tuesday, September 8th</li><li style="text-align:justify;">Cantor Healthcare Conference: fireside chat at 3:20 pm ET and available to host investor meetings on Wednesday, September 9th</li><li style="text-align:justify;">Citi’s 2026 Biopharma Back to School Summit: available http://www.streetinsider.com/Globe+Newswire/Aquestive+Therapeutics+to+Participate+in+Upcoming+September+Investor+Conferences/27008559.html Tue, 01 Sep 2026 07:00:00 -0400 AQST http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Aquestive+Therapeutics%2C+++For%3A+Aug+17++Filed+by%3A+Barber+Daniel/26944362.html si-local-file:///var/storage/secattach/20260818/26944362.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Aquestive+Therapeutics%2C+++For%3A+Aug+17++Filed+by%3A+Barber+Daniel/26944362.html Tue, 18 Aug 2026 16:13:00 -0400 AQST O.37573242 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Aquestive+Therapeutics%2C+++For%3A+Aug+17++Filed+by%3A+Barber+Daniel/26944362.html si-local-file:///var/storage/secattach/20260818/26944362.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Aquestive+Therapeutics%2C+++For%3A+Aug+17++Filed+by%3A+Barber+Daniel/26944362.html Tue, 18 Aug 2026 16:13:00 -0400 AQST O.37573242 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Aquestive+Therapeutics%2C+++For%3A+Aug+14++Filed+by%3A+Korczynski+Sherry/26939039.html si-local-file:///var/storage/secattach/20260817/26939039.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Aquestive+Therapeutics%2C+++For%3A+Aug+14++Filed+by%3A+Korczynski+Sherry/26939039.html Mon, 17 Aug 2026 17:34:00 -0400 AQST O.37573242 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Aquestive+Therapeutics%2C+++For%3A+Aug+14++Filed+by%3A+Korczynski+Sherry/26939039.html si-local-file:///var/storage/secattach/20260817/26939039.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Aquestive+Therapeutics%2C+++For%3A+Aug+14++Filed+by%3A+Korczynski+Sherry/26939039.html Mon, 17 Aug 2026 17:34:00 -0400 AQST O.37573242 http://www.streetinsider.com/SEC+Filings/Form++144++++++++Aquestive+Therapeutics%2C++++++++++++++++Filed+by%3A+Barber+Daniel/26938433.html si-local-file:///var/storage/secattach/20260817/26938433.html http://www.streetinsider.com/SEC+Filings/Form++144++++++++Aquestive+Therapeutics%2C++++++++++++++++Filed+by%3A+Barber+Daniel/26938433.html Mon, 17 Aug 2026 16:35:00 -0400 AQST O.37573242 http://www.streetinsider.com/SEC+Filings/Form++144++++++++Aquestive+Therapeutics%2C++++++++++++++++Filed+by%3A+Barber+Daniel/26938433.html si-local-file:///var/storage/secattach/20260817/26938433.html http://www.streetinsider.com/SEC+Filings/Form++144++++++++Aquestive+Therapeutics%2C++++++++++++++++Filed+by%3A+Barber+Daniel/26938433.html Mon, 17 Aug 2026 16:35:00 -0400 AQST O.37573242 http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Aquestive+Therapeutics%2C+++For%3A+Jun+30/26905820.html si-local-file:///var/storage/secattach/20260811/26905820.html http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Aquestive+Therapeutics%2C+++For%3A+Jun+30/26905820.html Tue, 11 Aug 2026 16:11:00 -0400 AQST O.37573242 http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Aquestive+Therapeutics%2C+++For%3A+Jun+30/26905820.html si-local-file:///var/storage/secattach/20260811/26905820.html http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Aquestive+Therapeutics%2C+++For%3A+Jun+30/26905820.html Tue, 11 Aug 2026 16:11:00 -0400 AQST O.37573242 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Aquestive+Therapeutics%2C+++For%3A+Aug+11/26905658.html si-local-file:///var/storage/secattach/20260811/26905658.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Aquestive+Therapeutics%2C+++For%3A+Aug+11/26905658.html Tue, 11 Aug 2026 16:07:00 -0400 AQST O.37573242 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Aquestive+Therapeutics%2C+++For%3A+Aug+11/26905658.html si-local-file:///var/storage/secattach/20260811/26905658.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Aquestive+Therapeutics%2C+++For%3A+Aug+11/26905658.html Tue, 11 Aug 2026 16:07:00 -0400 AQST O.37573242 http://www.streetinsider.com/Press+Releases/Aquestive+Therapeutics+Reports+Second+Quarter+2026+Financial+Results+and+Provides+Business+Update+/26905402.html <ul><li><em>Successfully completed human factors validation study and pharmacokinetic study for Anaphylm™ (dibutepinephrine) sublingual film</em></li><li><em>Remains on track to resubmit Anaphylm NDA to the FDA in Q3 2026</em></li><li><em>Continues pre-launch medical affairs activities and payer engagement</em></li><li><em>On track to begin ex-U.S. filings of Anaphylm in Q4 2026</em></li><li><em>Company to host investor call on August 12, 2026, at 8:00 a.m. ET</em></li></ul> <p align="justify">WARREN, N.J., Aug. 11, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) ("Aquestive" or the "Company"), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced financial results for the http://www.streetinsider.com/Press+Releases/Aquestive+Therapeutics+Reports+Second+Quarter+2026+Financial+Results+and+Provides+Business+Update+/26905402.html Tue, 11 Aug 2026 16:01:00 -0400 AQST http://www.streetinsider.com/Globe+Newswire/Aquestive+Therapeutics+Reports+Second+Quarter+2026+Financial+Results+and+Provides+Business+Update+/26905402.html <ul><li><em>Successfully completed human factors validation study and pharmacokinetic study for Anaphylm™ (dibutepinephrine) sublingual film</em></li><li><em>Remains on track to resubmit Anaphylm NDA to the FDA in Q3 2026</em></li><li><em>Continues pre-launch medical affairs activities and payer engagement</em></li><li><em>On track to begin ex-U.S. filings of Anaphylm in Q4 2026</em></li><li><em>Company to host investor call on August 12, 2026, at 8:00 a.m. ET</em></li></ul> <p align="justify">WARREN, N.J., Aug. 11, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) ("Aquestive" or the "Company"), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced financial results for the http://www.streetinsider.com/Globe+Newswire/Aquestive+Therapeutics+Reports+Second+Quarter+2026+Financial+Results+and+Provides+Business+Update+/26905402.html Tue, 11 Aug 2026 16:01:00 -0400 AQST http://www.streetinsider.com/Press+Releases/Aquestive+Therapeutics+Reports+Second+Quarter+2026+Financial+Results+and+Provides+Business+Update/26905416.html <ul><li><em>Successfully completed human factors validation study and pharmacokinetic study for Anaphylm™ (dibutepinephrine) sublingual film</em></li><li><em>Remains on track to resubmit Anaphylm NDA to the FDA in Q3 2026</em></li><li><em>Continues pre-launch medical affairs activities and payer engagement</em></li><li><em>On track to begin ex-U.S. filings of Anaphylm in Q4 2026</em></li><li><em>Company to host investor call on August 12, 2026, at 8:00 a.m. ET</em></li></ul> <p align="justify">WARREN, N.J., Aug. 11, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (&quot;Aquestive&quot; or the &quot;Company&quot;), a pharmaceutical company advancing medicines to bring meaningful improvement to patients&apos; lives through innovative science and delivery technologies, today announced financial results for the http://www.streetinsider.com/Press+Releases/Aquestive+Therapeutics+Reports+Second+Quarter+2026+Financial+Results+and+Provides+Business+Update/26905416.html Tue, 11 Aug 2026 16:01:00 -0400 A.02429381 A.03620480 A.06822034 A.13193403 AQST O.00183299 O.06200738 O.20026344 O.37573242 O.41197767 http://www.streetinsider.com/Press+Releases/Aquestive+Therapeutics+Reports+Second+Quarter+2026+Financial+Results+and+Provides+Business+Update/26905416.html <ul><li><em>Successfully completed human factors validation study and pharmacokinetic study for Anaphylm™ (dibutepinephrine) sublingual film</em></li><li><em>Remains on track to resubmit Anaphylm NDA to the FDA in Q3 2026</em></li><li><em>Continues pre-launch medical affairs activities and payer engagement</em></li><li><em>On track to begin ex-U.S. filings of Anaphylm in Q4 2026</em></li><li><em>Company to host investor call on August 12, 2026, at 8:00 a.m. ET</em></li></ul> <p align="justify">WARREN, N.J., Aug. 11, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (&quot;Aquestive&quot; or the &quot;Company&quot;), a pharmaceutical company advancing medicines to bring meaningful improvement to patients&apos; lives through innovative science and delivery technologies, today announced financial results for the http://www.streetinsider.com/Press+Releases/Aquestive+Therapeutics+Reports+Second+Quarter+2026+Financial+Results+and+Provides+Business+Update/26905416.html Tue, 11 Aug 2026 16:01:00 -0400 A.02429381 A.03620480 A.06822034 A.13193403 AQST O.00183299 O.06200738 O.20026344 O.37573242 O.41197767 http://www.streetinsider.com/Press+Releases/Aquestive+Therapeutics+Reports+Second+Quarter+2026+Financial+Results+and+Provides+Business+Update/26905416.html <ul><li><em>Successfully completed human factors validation study and pharmacokinetic study for Anaphylm™ (dibutepinephrine) sublingual film</em></li><li><em>Remains on track to resubmit Anaphylm NDA to the FDA in Q3 2026</em></li><li><em>Continues pre-launch medical affairs activities and payer engagement</em></li><li><em>On track to begin ex-U.S. filings of Anaphylm in Q4 2026</em></li><li><em>Company to host investor call on August 12, 2026, at 8:00 a.m. ET</em></li></ul> <p align="justify">WARREN, N.J., Aug. 11, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (&quot;Aquestive&quot; or the &quot;Company&quot;), a pharmaceutical company advancing medicines to bring meaningful improvement to patients&apos; lives through innovative science and delivery technologies, today announced financial results for the http://www.streetinsider.com/Press+Releases/Aquestive+Therapeutics+Reports+Second+Quarter+2026+Financial+Results+and+Provides+Business+Update/26905416.html Tue, 11 Aug 2026 16:01:00 -0400 A.02429381 A.03620480 A.06822034 A.13193403 AQST O.00183299 O.06200738 O.20026344 O.37573242 O.41197767 http://www.streetinsider.com/Press+Releases/Aquestive+Therapeutics+Reports+Second+Quarter+2026+Financial+Results+and+Provides+Business+Update/26905416.html <ul><li><em>Successfully completed human factors validation study and pharmacokinetic study for Anaphylm™ (dibutepinephrine) sublingual film</em></li><li><em>Remains on track to resubmit Anaphylm NDA to the FDA in Q3 2026</em></li><li><em>Continues pre-launch medical affairs activities and payer engagement</em></li><li><em>On track to begin ex-U.S. filings of Anaphylm in Q4 2026</em></li><li><em>Company to host investor call on August 12, 2026, at 8:00 a.m. ET</em></li></ul> <p align="justify">WARREN, N.J., Aug. 11, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (&quot;Aquestive&quot; or the &quot;Company&quot;), a pharmaceutical company advancing medicines to bring meaningful improvement to patients&apos; lives through innovative science and delivery technologies, today announced financial results for the http://www.streetinsider.com/Press+Releases/Aquestive+Therapeutics+Reports+Second+Quarter+2026+Financial+Results+and+Provides+Business+Update/26905416.html Tue, 11 Aug 2026 16:01:00 -0400 A.02429381 A.03620480 A.06822034 A.13193403 AQST O.00183299 O.06200738 O.20026344 O.37573242 O.41197767 http://www.streetinsider.com/Press+Releases/Aquestive+Therapeutics+Reports+Second+Quarter+2026+Financial+Results+and+Provides+Business+Update/26905416.html <ul><li><em>Successfully completed human factors validation study and pharmacokinetic study for Anaphylm™ (dibutepinephrine) sublingual film</em></li><li><em>Remains on track to resubmit Anaphylm NDA to the FDA in Q3 2026</em></li><li><em>Continues pre-launch medical affairs activities and payer engagement</em></li><li><em>On track to begin ex-U.S. filings of Anaphylm in Q4 2026</em></li><li><em>Company to host investor call on August 12, 2026, at 8:00 a.m. ET</em></li></ul> <p align="justify">WARREN, N.J., Aug. 11, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (&quot;Aquestive&quot; or the &quot;Company&quot;), a pharmaceutical company advancing medicines to bring meaningful improvement to patients&apos; lives through innovative science and delivery technologies, today announced financial results for the http://www.streetinsider.com/Press+Releases/Aquestive+Therapeutics+Reports+Second+Quarter+2026+Financial+Results+and+Provides+Business+Update/26905416.html Tue, 11 Aug 2026 16:01:00 -0400 A.02429381 A.03620480 A.06822034 A.13193403 AQST O.00183299 O.06200738 O.20026344 O.37573242 O.41197767 http://www.streetinsider.com/Press+Releases/Aquestive+Therapeutics+Reports+Second+Quarter+2026+Financial+Results+and+Provides+Business+Update/26905416.html <ul><li><em>Successfully completed human factors validation study and pharmacokinetic study for Anaphylm™ (dibutepinephrine) sublingual film</em></li><li><em>Remains on track to resubmit Anaphylm NDA to the FDA in Q3 2026</em></li><li><em>Continues pre-launch medical affairs activities and payer engagement</em></li><li><em>On track to begin ex-U.S. filings of Anaphylm in Q4 2026</em></li><li><em>Company to host investor call on August 12, 2026, at 8:00 a.m. ET</em></li></ul> <p align="justify">WARREN, N.J., Aug. 11, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (&quot;Aquestive&quot; or the &quot;Company&quot;), a pharmaceutical company advancing medicines to bring meaningful improvement to patients&apos; lives through innovative science and delivery technologies, today announced financial results for the http://www.streetinsider.com/Press+Releases/Aquestive+Therapeutics+Reports+Second+Quarter+2026+Financial+Results+and+Provides+Business+Update/26905416.html Tue, 11 Aug 2026 16:01:00 -0400 A.02429381 A.03620480 A.06822034 A.13193403 AQST O.00183299 O.06200738 O.20026344 O.37573242 O.41197767 http://www.streetinsider.com/Press+Releases/Aquestive+Therapeutics+Reports+Second+Quarter+2026+Financial+Results+and+Provides+Business+Update/26905416.html <ul><li><em>Successfully completed human factors validation study and pharmacokinetic study for Anaphylm™ (dibutepinephrine) sublingual film</em></li><li><em>Remains on track to resubmit Anaphylm NDA to the FDA in Q3 2026</em></li><li><em>Continues pre-launch medical affairs activities and payer engagement</em></li><li><em>On track to begin ex-U.S. filings of Anaphylm in Q4 2026</em></li><li><em>Company to host investor call on August 12, 2026, at 8:00 a.m. ET</em></li></ul> <p align="justify">WARREN, N.J., Aug. 11, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (&quot;Aquestive&quot; or the &quot;Company&quot;), a pharmaceutical company advancing medicines to bring meaningful improvement to patients&apos; lives through innovative science and delivery technologies, today announced financial results for the http://www.streetinsider.com/Press+Releases/Aquestive+Therapeutics+Reports+Second+Quarter+2026+Financial+Results+and+Provides+Business+Update/26905416.html Tue, 11 Aug 2026 16:01:00 -0400 A.02429381 A.03620480 A.06822034 A.13193403 AQST O.00183299 O.06200738 O.20026344 O.37573242 O.41197767 http://www.streetinsider.com/Press+Releases/Aquestive+Therapeutics+Reports+Second+Quarter+2026+Financial+Results+and+Provides+Business+Update/26905416.html <ul><li><em>Successfully completed human factors validation study and pharmacokinetic study for Anaphylm™ (dibutepinephrine) sublingual film</em></li><li><em>Remains on track to resubmit Anaphylm NDA to the FDA in Q3 2026</em></li><li><em>Continues pre-launch medical affairs activities and payer engagement</em></li><li><em>On track to begin ex-U.S. filings of Anaphylm in Q4 2026</em></li><li><em>Company to host investor call on August 12, 2026, at 8:00 a.m. ET</em></li></ul> <p align="justify">WARREN, N.J., Aug. 11, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (&quot;Aquestive&quot; or the &quot;Company&quot;), a pharmaceutical company advancing medicines to bring meaningful improvement to patients&apos; lives through innovative science and delivery technologies, today announced financial results for the http://www.streetinsider.com/Press+Releases/Aquestive+Therapeutics+Reports+Second+Quarter+2026+Financial+Results+and+Provides+Business+Update/26905416.html Tue, 11 Aug 2026 16:01:00 -0400 A.02429381 A.03620480 A.06822034 A.13193403 AQST O.00183299 O.06200738 O.20026344 O.37573242 O.41197767 http://www.streetinsider.com/Press+Releases/Aquestive+Therapeutics+Reports+Second+Quarter+2026+Financial+Results+and+Provides+Business+Update/26905416.html <ul><li><em>Successfully completed human factors validation study and pharmacokinetic study for Anaphylm™ (dibutepinephrine) sublingual film</em></li><li><em>Remains on track to resubmit Anaphylm NDA to the FDA in Q3 2026</em></li><li><em>Continues pre-launch medical affairs activities and payer engagement</em></li><li><em>On track to begin ex-U.S. filings of Anaphylm in Q4 2026</em></li><li><em>Company to host investor call on August 12, 2026, at 8:00 a.m. ET</em></li></ul> <p align="justify">WARREN, N.J., Aug. 11, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (&quot;Aquestive&quot; or the &quot;Company&quot;), a pharmaceutical company advancing medicines to bring meaningful improvement to patients&apos; lives through innovative science and delivery technologies, today announced financial results for the http://www.streetinsider.com/Press+Releases/Aquestive+Therapeutics+Reports+Second+Quarter+2026+Financial+Results+and+Provides+Business+Update/26905416.html Tue, 11 Aug 2026 16:01:00 -0400 A.02429381 A.03620480 A.06822034 A.13193403 AQST O.00183299 O.06200738 O.20026344 O.37573242 O.41197767 http://www.streetinsider.com/Press+Releases/Aquestive+Therapeutics+Reports+Second+Quarter+2026+Financial+Results+and+Provides+Business+Update/26905416.html <ul><li><em>Successfully completed human factors validation study and pharmacokinetic study for Anaphylm™ (dibutepinephrine) sublingual film</em></li><li><em>Remains on track to resubmit Anaphylm NDA to the FDA in Q3 2026</em></li><li><em>Continues pre-launch medical affairs activities and payer engagement</em></li><li><em>On track to begin ex-U.S. filings of Anaphylm in Q4 2026</em></li><li><em>Company to host investor call on August 12, 2026, at 8:00 a.m. ET</em></li></ul> <p align="justify">WARREN, N.J., Aug. 11, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (&quot;Aquestive&quot; or the &quot;Company&quot;), a pharmaceutical company advancing medicines to bring meaningful improvement to patients&apos; lives through innovative science and delivery technologies, today announced financial results for the http://www.streetinsider.com/Press+Releases/Aquestive+Therapeutics+Reports+Second+Quarter+2026+Financial+Results+and+Provides+Business+Update/26905416.html Tue, 11 Aug 2026 16:01:00 -0400 A.02429381 A.03620480 A.06822034 A.13193403 AQST O.00183299 O.06200738 O.20026344 O.37573242 O.41197767 http://www.streetinsider.com/Globe+Newswire/Aquestive+Therapeutics+Reports+Second+Quarter+2026+Financial+Results+and+Provides+Business+Update/26905416.html <ul><li><em>Successfully completed human factors validation study and pharmacokinetic study for Anaphylm™ (dibutepinephrine) sublingual film</em></li><li><em>Remains on track to resubmit Anaphylm NDA to the FDA in Q3 2026</em></li><li><em>Continues pre-launch medical affairs activities and payer engagement</em></li><li><em>On track to begin ex-U.S. filings of Anaphylm in Q4 2026</em></li><li><em>Company to host investor call on August 12, 2026, at 8:00 a.m. ET</em></li></ul> <p align="justify">WARREN, N.J., Aug. 11, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (&quot;Aquestive&quot; or the &quot;Company&quot;), a pharmaceutical company advancing medicines to bring meaningful improvement to patients&apos; lives through innovative science and delivery technologies, today announced financial results for the http://www.streetinsider.com/Globe+Newswire/Aquestive+Therapeutics+Reports+Second+Quarter+2026+Financial+Results+and+Provides+Business+Update/26905416.html Tue, 11 Aug 2026 16:01:00 -0400 A.02429381 A.03620480 A.06822034 A.13193403 AQST O.00183299 O.06200738 O.20026344 O.37573242 O.41197767